Phentermine/Topiramate: Pediatric First Approval.
Adult
Adolescent
Humans
Child
Topiramate
/ therapeutic use
Anti-Obesity Agents
/ adverse effects
Sympathomimetics
/ therapeutic use
Delayed-Action Preparations
Non-alcoholic Fatty Liver Disease
Diabetes Mellitus, Type 2
/ drug therapy
Weight Loss
Phentermine
/ adverse effects
Obesity
/ complications
Fructose
/ therapeutic use
Sleep Apnea Syndromes
/ drug therapy
Journal
Paediatric drugs
ISSN: 1179-2019
Titre abrégé: Paediatr Drugs
Pays: Switzerland
ID NLM: 100883685
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
pubmed:
5
9
2022
medline:
27
10
2022
entrez:
4
9
2022
Statut:
ppublish
Résumé
Phentermine/topiramate extended-release capsule (Qsymia
Identifiants
pubmed: 36059008
doi: 10.1007/s40272-022-00532-z
pii: 10.1007/s40272-022-00532-z
doi:
Substances chimiques
Topiramate
0H73WJJ391
Anti-Obesity Agents
0
Sympathomimetics
0
Delayed-Action Preparations
0
Phentermine
C045TQL4WP
Fructose
30237-26-4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
715-720Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Centers for Disease Control and Prevention. Childhood obesity facts. 2022. https://www.cdc.gov/obesity/data/childhood.html . Accessed 24 July 2022.
Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709–57.
doi: 10.1210/jc.2016-2573
VIVUS LLC. QSYMIA (phentermine and topiramate extended-release capsules): US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf . Accessed 18 July 2022.
VIVUS LLC. FDA approves QSYMIA
Catalent Pharma Solutions. Catalent enters into commercial supply agreement with VIVUS for Qsymia™ once-daily combination-extended-release capsules [media release]. 2 Oct 2012. https://www.catalent.com .
Vivus. VIVUS announces acquisition of topiramate-related patents from Janssen Pharmaceuticals [media release]. 25 Aug 2014. https://ir.vivus.com/news-releases/news-release-details/vivus-announces-acquisition-topiramate-related-patents-janssen .
Vivus. VIVUS and Alvogen announce marketing agreement for Qsymia
Hsia DS, Gosselin NH, Williams J, et al. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity. Diabetes Obes Metab. 2020;22(4):480–91.
doi: 10.1111/dom.13910
Kelly Aaron S, Bensignor Megan O, Hsia Daniel S, et al. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6):EVIDoa2200014.